SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc is trending as chatter around AI AR smartglasses, potential buyouts, and increased user engagement drive interest. The community is buzzing about the company's potential to compete with tech giants in the AR space, along with speculation on how it might benefit from regulatory changes impacting competitors like TikTok. High options volume and bullish sentiment suggest strong conviction in the stock's near-term prospects.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amidst discussions about media censorship and the First Amendment, sparked by actions against Jimmy Kimmel's show. Community members are actively debating the implications for free speech and perceived biases in media outlets. The stock's activity also intersects with broader conversations around political polarization and cultural divides.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending due to its rebranding as Solmate, a Solana-backed digital asset treasury, fueled by a substantial $300M private investment and ARK Invest's involvement; however, concerns about potential dilution from pending share registrations are also being discussed. Community members are actively debating the stock's potential for further gains versus the risk of a price correction, with some pointing to its low float and others highlighting potential downside risks.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Recent news regarding Jimmy Kimmel's show suspension has sparked heated debate among investors, with community perspectives split between concerns over free speech and potential political bias.  Many subscribers are publicly announcing canceling subscriptions. Disney's balancing act between content, political sensitivities, and streaming profitability is now under scrutiny.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending following the release of its earnings report, which initially beat expectations but was followed by concerns over forward guidance, particularly related to tariffs. Community discussions are centered on the impact of the updated outlook and the stock's potential trajectory in light of these uncertainties. Some investors see a buying opportunity, while others express caution about the company's prospects.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as the community debates its potential amid technical analysis pointing to key resistance levels and discussions around leveraged positions. Some traders express frustration with the coin's performance and question its long-term viability, while others remain optimistic, citing upcoming catalysts and potential partnerships. Overall, the conversation is focused on near-term price action and the factors that could influence its trajectory.

FatPipe, Inc. engages in the development of software-defined wide area network (SD-WAN) solutions for organizations, including enterprises, communication service providers, security service providers, government organizations, and other middle-market companies. Its products include WARP, MPVPN, SD-WAN, Fatpipe Orchestrator, Next Gen Firewall, 5G and LTE, FatPipe Total Security 360, SASE, SIEM, EnterpriseView, and Cloud Connect. The company was founded by Ragula Bhaskar and Sanchaita Datta on October 14, 2010 and is headquartered in Salt Lake City, UT.

Fatpipe Inc.

FatPipe, Inc. Common Stock

FATN is trending amid community discussions about its low float, potential short squeeze, and recent trading activity, with some speculating about a possible breakout. An interview with the CEO is circulating, and the stock's addition to the Russell indexes is being noted. Some investors are closely watching FATN due to its financial performance and anticipation of upcoming news and earnings reports.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to analyst upgrades and strong AI-driven demand for memory chips, fueling discussions about its potential to reach new highs before earnings. Community members are weighing the potential for continued gains against concerns of being overbought, debating whether to take profits or hold through the upcoming earnings report. Upgrades cite tailwinds from high-bandwidth memory and a recovery in commodity memory pricing.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors digest recent iPhone 17 launch details, with strong early demand reported in Asia despite some complaints about scratches. The community is closely watching sales figures and upgrades from analysts, with some anticipating a breakout to new highs and potential involvement in a TikTok deal. Broader discussions include the company's AI strategy and the potential impact of interest rate decisions.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

AlphaVest Acquisition Corp (ATMV) is trending due to significant price volatility, leading to multiple trading halts. The community is actively discussing its low float, potential merger agreement, and possible short squeeze, with some traders reporting substantial gains. Interest may also stem from ATMV's focus on Asian markets and comparisons to other SPACs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of +5.75% and +3.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates

Rigel (RIGL) delivered earnings and revenue surprises of +66.50% and +28.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Nektar Gears Up to Report Q2 Earnings: What's in the Cards?

NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street analysts sharply upgraded their outlook on Nektar Therapeutics on Wednesday following positive topline results from the company’s Phase 2b REZOLVE-AD trial of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.Nektar Therapeutics’ stock closed Wednesday up 19.1% at $29.12 and added another 1.1% after hours to $29.43.Jefferies lifted its price target from $2 to $69, citing improved confidence in rezpegaldesleukin’s efficacy and safety in what it described as an “enormous disease space.”&nbsp;The firm maintained a ‘Buy’ rating.Additionally, BTIG raised its target to $100 from $60, calling the stock a “pound the table BUY” and noting that all three dose arms achieved statistical significance across primary and secondary endpoints at 16 weeks.&nbsp;BTIG analysts said the “robust” data support rezpegaldesleukin’s status as a novel mechanism of action with&nbsp;the potential to outperform current therapies.Meanwhile, H.C. Wainwright was the most bullish, increasing its target from $6.50 to $120 and calling the results “paradigm-shifting.”&nbsp;The firm said rezpeg’s highly differentiated profile could reshape the atopic dermatitis treatment landscape and noted further improvement may come in the 36-week maintenance data expected in Q1 2026.Nektar said its primary 16-week induction data&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nektar-therapeutics-announces-positive-data-from-eczema-drug-in-mid-stage-trial/chm40c0RR3i">met its primary endpoint</a>, with a statistically significant improvement in Eczema Area and Severity Index (EASI) in all dose arms versus placebo.&nbsp;The company also met its secondary endpoints, which include EASI-75, EASI-50, BSA score, vIGA-AD 0/1, Itch NRS, and EASI-90 at the highest dose.&nbsp;Safety was consistent with previous data, and&nbsp;blood biomarker data showed strong on-target, dose-dependent activity.The results will be shared at a medical conference later in 2025. The company expects to report Phase 2b data for rezpeg in alopecia areata in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said that Nektar could touch $100 as early as tomorrow.&nbsp;<stembedurl>https://stocktwits.com/LFG2030/message/619030106</stembedurl>Another speculated that, barring an immediate equity offering, the stock might reach $40 in the next session.<stembedurl>https://stocktwits.com/Majlo/message/619029852</stembedurl>Others remained cautious, noting&nbsp;that dilutive financings often follow such rallies.&nbsp;One user said an offering was likely “incoming,” potentially in the $15 range.<stembedurl>https://stocktwits.com/BIGPHILLY/message/619028491</stembedurl>Still, some bulls pushed back, dismissing near-term offering concerns as "bear hopium" and predicting a move to $49 to fill the gap, with all-time highs (ATH) as the next target.<stembedurl>https://stocktwits.com/Da_Closer/message/619027710</stembedurl>Nektar’s stock has doubled its value so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis. 

Equity

NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study

Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.

Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.nektar.com/news-releases/news-release-details/rezolve-ad-phase-2b-study-rezpegaldesleukin-meets-primary-and">announced</a> that its mid-stage study evaluating Rezpegaldesleukin in atopic dermatitis demonstrated improvement in area affected and severity.The global Phase 2b study is being conducted in 393 patients with moderate-to-severe atopic dermatitis. The company announced that, at week 16, patients who received Rezpegaldesleukin showed improvement in eczema area and severity score from baseline, as compared to placebo, using a widely used index.The trial also demonstrated that Rezpegaldesleukin reduced disease severity by as much as 90% or more with higher doses of the drug.Atopic dermatitis is the most common type of eczema, affecting approximately 30 million people in the U.S., according to Nektar. It is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inﬂammation.Rezpegaldesleukin is an investigational therapy that may address the underlying immune system imbalance in people with many autoimmune and inflammatory conditions.It targets the interleukin-2 receptor complex in the body to stimulate the proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, Rezpegaldesleukin aims to restore the immune system's balance.The company is now looking forward to reporting results from its trial of Rezpegaldesleukin in alopecia areata, an autoimmune disease that causes hair loss, in the fourth quarter of this year.Following the update from the company, H.C. Wainwright raised the firm's price target on Nektar to $120 from $6.50 while keeping a ‘Buy’ rating on the shares.On Stocktwits, retail sentiment around Nektar jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_04_09_PM_png_6458c1b61c.webp" alt="NKTR's Sentiment Meter and Message Volume as of 12 p.m. ET on June 24, 2025 | Source: Stocktwits" width="628" height="66"><figcaption>NKTR's Sentiment Meter and Message Volume as of 12 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the user to jump as much as 150% later today.<stembedurl>https://stocktwits.com/US_Bull/message/618826543</stembedurl><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> is up by 66% this year and by about 32% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jerome-powell-tells-congress-fed-can-wait-on-rate-cuts-despite-pressure-from-trump/chm4hMMRR3h">Jerome Powell Tells Congress Fed Is ‘Well Positioned To Wait’ On Rate Cuts Despite Mounting Pressure From Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising Further

Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16.

Nektar Therapeutics shares jumped 35.3% in&nbsp;extended trading Monday after the company said it&nbsp;would release topline results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for atopic dermatitis on Tuesday.The stock closed Monday’s regular session up 12.1% at $9.54.The experimental treatment is called NKTR-358 or REZPEG. It's a first-in-class regulatory T-cell (Treg) stimulator in development for autoimmune and inflammatory skin diseases.Nektar will hold an investor webcast at 8:15 a.m. ET on June 24 to discuss the 16-week induction data from the global trial.The stock reaction follows CEO Howard Robin's remarks in May that the company was on track to deliver trial results in June, positioning rezpegaldesleukin to emerge as an “important novel mechanism” to treat patients with chronic autoimmune disorders.The company also reiterated that topline data from a separate Phase 2 trial in alopecia areata are expected by December.In its most recent earnings report, Nektar posted a Q1 adjusted loss of&nbsp;$0.22 per share, wider than the consensus estimate of&nbsp;$0.19 loss per share. Revenue came in at $10.5 million, below analysts' expectations of $15.36 million.Robin also said Nektar is advancing other pipeline assets, including NKTR-0165 for multiple sclerosis and ulcerative colitis and a bispecific antibody candidate, NKTR-0166, both targeting the TNFR2 receptor.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,600% surge in 24-hour message volume.One user expects shares of Nektar to climb to the $14–$15 range overnight.&nbsp;<stembedurl>https://stocktwits.com/RealBobbyAxelrod/message/618755635</stembedurl>Another user noted the strong after-hours move likely reflected optimism, but expressed uncertainty about holding the position, saying they were tempted to take some profits.<stembedurl>https://stocktwits.com/Patrick2343/message/618743686</stembedurl>The stock has declined 33.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, a biopharmaceutical company located on 3rd Street, in the Mission Bay District of San Francisco, California, October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours Away

Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$59.58
Prev Close	$51.07
Open	$55.61
Dividend Yield	0.00%
50-Day Moving Average	$30.20
Beta	1.91
Avg. Volume	653,115.57
PE Ratio	-6.74

52-Week High	$58.81
52-Week Low	$6.48
Market Capitalization	$1.12B
EPS (Annual)	-$8.68
Price to Book	-30.23
Revenue Per Employee	$1.61M
Enterprise Value/EBITDA	N/A

NKTR
Nektar Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NKTR News

NKTR Nektar Therapeutics